Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 2Terminated 1

Sponsor Class

OTHER 84NIH 26INDUSTRY 23OTHER_GOV 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 5Gastrointestinal 3Head & Neck 1

Conditions

Pancreatic Neoplasms 2Neoplasm Metastasis 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 30Capecitabine 26Fluorouracil 20Irinotecan 19tislelizumab 18apatinib 16Paclitaxel 13Cisplatin 13S 1 (combination) 12Radiotherapy 12Leucovorin 11Bevacizumab 11Laparoscopy 9Drug Therapy 9Cetuximab 9sintilimab 8Endoscopic Mucosal Resection 8Gemcitabine 7Docetaxel 7camrelizumab 6XELOX 6Surgical Procedures, Operative 6Radiation 6Propranolol 6Nivolumab 6Neoadjuvant Therapy 6Immune Checkpoint Inhibitors 6Folfox protocol 6Levoleucovorin 5HMPL-013 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER_GOV × Erlotinib Hydrochloride × Gastrointestinal × Clear all
NCT01608841 2015-02-18

The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib

Taipei Veterans General Hospital, Taiwan

Phase 2 Unknown
88 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00636883 2014-01-22

GEMOX-T

National Guard Health Affairs

Phase 2 Terminated
9 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT00784667 2010-11-30

Dux

Austin Health

Phase 2 Unknown
50 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡